OpenEHR modeling for genomics in clinical practice

Cecilia Mascia^{1,*} Paolo Uva¹ Simone Leo¹ Gianluigi Zanetti¹

¹ **CRS4: Center for Advanced Studies, Research and Development in Sardinia**

* cecilia.mascia@crs4.it

Abstract

The increasing usage of high throughput sequencing in personalized medicine brings new challenges to the realm of healthcare informatics. Patient records need to accommodate data of unprecedented size and complexity as well as keep track of their production process. In this work we present a solution for integrating genomic data into electronic health records via openEHR archetypes. We introduce new genomics-specific archetypes based on the popular variant call format and show their applicability to a practical use case. Finally, we discuss their structure in comparison with the HL7[®] FHIR[®] standard.

Keywords: genomics, openEHR, structured data, electronic health record, variant calling.

1 Introduction

Next generation sequencing (NGS) techniques have recently enabled a substantial advancement in the treatment of genetic disorders, paving the way for personalized therapies based on each patient's specific set of genomic variations. Whole-exome (WES) and whole-genome sequencing (WGS) have become increasingly common in the past years, thanks mainly to the progress and cost reduction in high-throughput sequencing technologies^{1,2}. This trend suggests that genomic data are going to play an increasingly important role within medical practice in the near future.

Entities related to a patient's clinical history can be modeled according to a spoke-hub paradigm, where the different actors (such as clinicians, specialists, hospitals, labs and the patient itself) all revolve around the Electronic Health Record (EHR), the central collection point of all clinical data provided by each actor. Due to its high relevance in modern healthcare, genomic

information should be a fundamental part of EHRs. In practice, however, most current EHR systems are not capable of handling such data^{1,2,3,4}, since their sheer size and complexity entail new technological challenges in terms of storage, integration, visualization, computational analysis, querying and presentation. Moreover, where supported, genomic information is often made available as unformatted plain text, whereas a structured, machine-readable format would greatly enhance its shareability and reusability. Finally, particular care must be taken to ensure interoperability with other medical informatics standards. These practical difficulties severely hinder the translation of genetic information into concrete clinical actions.

In this work we present a new openEHR⁵ model for genomic data produced in the context of sequence variation analysis, specifically focused on machine readability and computability. We show its applicability to a concrete use case and its interoperability with existing clinical standards. Finally, we discuss our approach in comparison with related work.

1.1 OpenEHR specifications

OpenEHR is an open standard for health data that focuses on the semantic interoperability between EHR systems. It adopts a multi-level modeling approach based upon the Reference Model (RM), a set of classes that represent logical EHR structures and demographic data. The next level consists of a library of *archetypes*, reusable models that define a maximal set of attributes related to a particular subject. Archetypes, in turn, can be combined into *templates*, hierarchical context-specific data sets. Archetypes and templates undergo an iterative web-based review process, at the end of which they are published in the official openEHR repository, the Clinical Knowledge Manager (CKM)⁶, and made available for clinical use.

Archetypes belong to four main groups: *compositions*, which represent commonly used clinical documents; *sections*, corresponding to document headings; *entries*, the most common and fundamental building blocks of an EHR (further divided into *observations*, *evaluations*, *instructions* and *actions*); *clusters*, reusable sub-structures that allow elements to be grouped and repeated. The model presented here makes use of the observation (data obtained by a direct observation or measurement) and cluster archetype classes.

Due to the amount of domain-specific expertise required, EHR systems development needs to be carried out in close cooperation with clinical stakeholders. The main challenges in this process

are establishing a common ground for communication between technicians and clinicians and addressing the frequent advancement of clinical knowledge. In the case of genomic content, this is further exacerbated by the size and structure issues discussed above. The multi-level openEHR approach helps mitigate these problems by separating structure and content: only the first modeling level (RM classes) is implemented in software, while formal definitions of clinical content (archetypes and templates) are external. This means that EHR repositories can be developed independently from the content they will store. Moreover, EHR systems can be kept small, maintainable and self-adaptable to archetypes and templates that may be developed in the future⁷. Finally, this decoupling facilitates contributions by non-technical professionals, who can formalize their clinical knowledge via user-friendly modeling tools.

1.2 Structured approach

Integrating NGS data into EHRs is hard due to two main reasons³:

- their size (up to hundreds of gigabytes) and complexity (e.g., irregular degree of nesting in laboratory test outputs);
- the way they are generated and manipulated, with processing pipelines where each step depends on a multitude of software parameters and resource databases.

Currently available EHR systems typically collect three types of data: granular (e.g., laboratory test results), text (e.g., pathology reports) and media (e.g., medical imaging). As mentioned earlier, due to the lack of specific data structures genomic data is often included in text form, which makes their analysis and reuse particularly cumbersome. The adoption of a structured format would greatly simplify the processing and transfer of clinical genomic data, effectively enhancing its medical value. The chosen format should enable the efficient management of complex clinical content by organizing it into standard reusable entities. At the same time, it should allow the specification of data semantics, while ensuring that the original meaning is preserved in case of sharing. Finally, it should preserve the data history, with regard to both the operations performed and the auxiliary resources involved in the transformation process (such as external databases, genomic references, etc.). In the remainder of this paper we show how to use the openEHR approach to address these issues.

2 Materials and methods

2.1 Genomic data

WGS and WES have rapidly changed research on the genetic causes of rare and complex diseases. Independently from the technology used, NGS data analysis can be broken down into two main steps⁸: the *analytic wet bench process* and the *bioinformatic analysis of sequence data* (Fig. 1).

Figure 1: Main NGS steps, grouped accordingly to the College of American Pathologists⁸.

The process starts with DNA extraction and its fragmentation into small pieces. NGS instruments produce billions of short sequence reads (strings representing ordered DNA nucleotides in a fragment) simultaneously in a single machine run. Reads are subsequently aligned (mapped) to a reference sequence through dedicated software, a computationally intensive operation due to the large size of the reference. Aligned reads are then processed to correct for technical biases and, finally, genomic variants (the differences between the sample and the reference) are identified and reported, along with additional information such as the coverage depth (average number of reads that align to known reference bases) and accuracy measures. Due to the large amount of variants that can be detected, generating useful results requires one or more filtering steps to prioritize potential disease-causing mutations^{9,10,11,12}. This is commonly done by annotating variants with references to public databases such as dbSNP¹³. Common scenarios in human NGS data analysis include the discovery of disease-associated variant(s) for mendelian disorder-

ders, the identification of candidate genes responsible for complex diseases and the detection of constitutional and somatic mutations in cancer studies⁹.

Genomic data can be seen as a multilayer structure composed of three levels:

- **Raw data**, the direct output of the sequencing process, consist of millions of short sequence reads, text strings containing the detected DNA nucleotides together with their associated quality scores (statistical predictions of accuracy).
- **Derived data** represents the observed variants, along with additional measurements (e.g., coverage);
- **Annotated data** corresponds to variants filtered according to additional a-priori information, as discussed above.

With respect to Fig. 1, the first level falls within the wet bench block, while the other two are part of the bioinformatic pipeline.

Figure 2: Schematic representation of a bioinformatic pipeline for NGS variant detection.

A common bioinformatic workflow for variant identification from NGS data includes the following steps¹⁴ (Fig. 2):

- **Alignment**: short reads are aligned to the reference to produce a file in SAM/BAM format¹⁵, sorted by genomic coordinate. Initial mappings are further processed to address technical biases (removal of duplicate sequences, recalibration of base quality scores).
- **Variant calling**: alignment files output by the previous step are processed to detect variations between the sample and the reference. Since variations may also arise from mapping and sequencing artifacts, variant calling software should carefully balance sensi-

tivity to minimize false positives. The output, typically in tabular format, contains the list of variant sites, the individual genotypes and additional information such as coverage and genotyping accuracy.

- **Variant annotation:** assigning functional information to genomic variants is a crucial step in the analysis of sequencing data, enabling researchers to focus on the potential disease-causing variants. Many types of biological information can be associated to variants: the position in transcript sets (e.g., UCSC, RefGene, GENCODE, ENSEMBL), whether the variant is known or novel based on dbSNP, the prediction of their impact on the protein structure and function according to different models (e.g., SIFT, PolyPhen2, LRT, MutationTaster, MutationAssessor, FATHMM), sequence conservation (e.g., PhyloP, PhastCons), known associations of the variant with diseases (e.g., OMIM, ClinVar) and allele frequency in reference populations (e.g., ESP6500, 1000 Genomes Project, gnomAD).

2.2 OpenEHR modeling approach

Figure 3: Block diagram of the process leading from data to clinical actions.

Figure 3 summarizes the context from a high level perspective: the clinician receives phenotypic and genetic (laboratory block) patient data, and interprets them in combination with prior clinical knowledge and experience to produce actionable results. It should be noted that, before reaching the clinical side, laboratory output should be reorganized to assume a structured form. The openEHR model allows to achieve this through the archetypes formalism.

As discussed above, genetic data sets are produced via complex pipelines that involve the use of different algorithms, parameters and reference entities. To provide a comprehensive and reusable model for genomic data, archetypes should be able to keep track of all this information

in a structured way. Since all of these elements can change over time, to ensure reproducibility we include this information as external references in our model.

Common openEHR modeling practice follows (possibly with recursion) these steps:

- define the data to be represented;
- search model repositories for reusable archetypes and, possibly, map existing archetype nodes with clinical attributes;
- create new archetypes or specialize existing ones for the specific domain being modeled.

In our case, the model has to represent the output of the bioinformatic pipeline, i.e., information about the variants detected at specific positions in the genome. Due to its wide adoption for the representation of genomic data, we have designed our archetypes to mirror the Variant Call Format (VCF)¹⁶. As shown in Fig. 4, a VCF file consists of meta-information lines, a header line and data lines (body).

Figure 4: The main section of a typical VCF file. Modified figure from the VCF specifications¹⁶.

Each row in the VCF body corresponds to a specific location in the genome where a single variation occurs, possibly with more than one alternate allele. All rows start with eight mandatory fields (although one or more could be empty): #CHROM, POS, ID, REF, ALT, QUAL, FILTER and INFO. If there are multiple alternate alleles called on at least one sample for a given position, these

are reported as a comma separated list under the **ALT** field. The **INFO** field (see Fig. 5) gives additional information on the observed variant, in a format specified in the meta-information.

```
##INFO=<ID=ID,Number=number,Type=type,Description="description",Source="source",Version="version">
```

Figure 5: The VCF **INFO** field¹⁶.

Sample-specific information (such as coverage or genotype accuracy), is encoded in the **FORMAT** column, whose structure is also specified in the meta-information block. In addition to the mandatory ones, VCF allows to specify additional fields to accommodate specific domain annotations. The most common ones have already been included in the model, while additional ones can be specified via custom clusters.

As mentioned earlier, before embarking on the creation of new archetypes, a thorough search of existing public domain ones must be performed. At the time of writing, no archetype in the international instance of the CKM⁶ was suitable for genomic data. To fill this gap, we developed a new set of archetypes that are described in Sec. 3. This work has been carried out with the LinkEHR Studio software developed by the Universitat Politècnica de València and VeraTech for Health¹⁷.

3 Results

Figure 6: Hierarchical organization of archetypes for genetic content. Existing archetypes are marked with a green border.

A few entities involved in the sequencing workflow — such as specimen and device — were already supported in the CKM, while others required the development of new archetypes, either from the ground up or as specializations of existing ones. Figure 6 shows a possible template

Concept	Type	Status
Genetic Test Result	OBSERVATION	In progress
Genetic Findings	CLUSTER	Created
Sequence Variation	CLUSTER	Created
Reference Sequence	CLUSTER	Created
Substitution Variant	CLUSTER	Created
Deletion Variant	CLUSTER	Created
Duplication Variant	CLUSTER	Created
Insertion Variant	CLUSTER	Created
Inversion Variant	CLUSTER	Created
Conversion Variant	CLUSTER	Created
Indel Variant	CLUSTER	Created
Repeated Sequence Variant	CLUSTER	Created

Table 1: Archetypes for genetic data.

for a laboratory report of genomic test results. The top level of the hierarchy is occupied by the composition *Report*, followed by the *Genetic Test Result* observation archetype, developed as a specialization of the existing *Laboratory Test Result*¹⁸; to represent actual genetic data we created a new *Genetic Findings* cluster, in turn articulated into a number of nested clusters for sequence variation, reference genome and individual variant types (see Table 1).

3.1 OBSERVATION-Genetic Test Result

Genetic Test Result models data from a genetic test performed on a patient, along with details of the previously established clinical condition and a description of the protocol. In addition to the attributes carried over from *Laboratory Test Result*, *Genetic Test Result* provides: information on the interpretation and reporting of sequence variations — in accordance with recommendations by the American College of Medical Genetics (ACMG)^{19,20} — in the data section; a representation of the method in the protocol section. The latter, in particular, allows to refer to the bioinformatic workflow as an external resource and to specify the version used to perform the calculation, in order to allow the reconstruction of the data history. With respect to the other archetypes presented here, *Genetic Test Result* is currently at an earlier development stage, and thus more likely to evolve in the near future.

3.2 CLUSTER-Genetic Findings

The *Genetic Findings* cluster (see Fig. 8) is meant to be used in the “test findings” slot of *Genetic Test Result*, and can in turn include one or more *Sequence Variation* archetypes to report about variations that are considered relevant for the test. Considering a row in a VCF file, the *Sequence Variation* archetype corresponds to the “standard” parts, while the customizable **INFO** section can be represented by existing fields in *Genetic Finding* or by one or more ad hoc extensions.

3.3 CLUSTER-Sequence Variation and supplementary clusters

The *Sequence Variation* archetype (see Fig. 9) is designed to contain the same data found in a VCF row. The position of the observation in the genome is given with respect to a reference sequence specified in the *Reference Sequence* archetype (Fig. 10). Following the nomenclature proposed by the Human Genome Variation Society (HGVS)¹, the most common variant types are: substitution, deletion, duplication, insertion, inversion, conversion, insertion-deletion (indel) and repeated sequence²¹. We developed a new cluster archetype for each of the above types (examples are shown in Fig. 11 and 12).

4 Discussion

4.1 Real use case application

WES has emerged as a powerful tool for the diagnosis of rare mendelian disorders, especially where standard approaches have failed. This technique focuses on the protein-coding regions of the genome that are more likely to harbour disease-causing variants associated with a particular phenotype. Initially used for research activities, WES is now entering clinics for diagnostic purposes, thanks to the decreasing costs of NGS technologies. A typical study design for the identification of pathogenic variants in rare diseases includes the patient and its parents, and optionally additional family members (affected or not). In this report, we use results related to the WES of one family member to show how openEHR archetypes can successfully describe the genomic information obtained from an NGS-based genetic test (Tables 2 and 5).

¹URL: <http://varnomen.hgvs.org/>

Figure 7: The OBSERVATION-Genetic Test Result Archetype.

Figure 8: The CLUSTER-Genetic Findings Archetype.

Figure 9: The CLUSTER-Sequence Variation Archetype.

Figure 10: The CLUSTER-Reference Sequence Archetype.

Figure 11: The CLUSTER-Indel Variant Archetype.

Figure 12: The CLUSTER-Repeated Sequence Variant Archetype.

Attribute	Use case 1	Use case 2
Genetic Findings		
Findings		
[SLOT] Sequence Variation Annotations		
Transcript annotation		
[SLOT]: Reference sequence	NM_015557	NM_014981
Feature	missense	frameshift
DNA position	c.5249C>T	c.3612_3612delG
Protein position	p.T1750M	p.K1205Rfs*15
Predict impact		
[SLOT]: Bioinformatic calculation tool	CADD	MutationTaster
Score	23.8	1
Qualitative prediction	Damaging	Damaging
Conservation		
[SLOT]: Bioinformatic calculation tool	PhastCons7-way	PhastCons46-way
Score	1	0.988
Allele frequency		
[SLOT]: Bioinformatic calculation tool	ESP6500AA	1000 Genomes
Score	0.000454	NA
Info		
ID	FS	ExcessHet
Description	Fisher strand bias	Excess heterozygosity
Value	4.139	3.0103
[SLOT]: Extension		

Table 2: Sample usage of the Genetic Findings archetype

4.2 Interoperability: comparison with the HL7[®] FHIR[®] standard

This section discusses the interoperability of the proposed model with the one developed by the HL7[®] Clinical Genomics Work Group as part of the FHIR[®] standard²². HL7[®] FHIR[®]²³ is a standard for exchanging healthcare information that represents granular clinical concepts through basic building blocks called *resources*. Resources are relatively generic and have to be adapted to specific use cases. When a use case is common enough, it may become part of the specification itself as a *profile*. Genomics support in FHIR[®] consists of four profiles and a resource. The most relevant for this work are the *Observation* profile and the *Sequence* resource. The former, which adapts the *Observation* resource to the genomic context, is used for reporting interpretative genetic information mainly related to variant test results. The latter is instead used to describe an atomic sequence which contains alignment test results and multiple variations. Despite their different reference models, both openEHR and FHIR[®] can adequately model genetic data, albeit with different degrees of nesting: the openEHR structure is [OBS] Genetic Test Result → [CLUS] Genetic Findings → [CLUS] Sequence Variation → [CLUS] Variant, while the FHIR[®] one is Observation-Genetics → Sequence. The latter,

Attribute	Use case 1	Use case 2
Sequence Variation		
Genomic location		
[SLOT]Reference Sequence	NC_000001.10 Homo sapiens chromosome 1, GRCh37.p13 Primary Assembly	NC_000003.11 Homo sapiens chromosome 3, GRCh37.p13 Primary Assembly
Genome assembly	GRCh37.p13	GRCh37.p13
Genomic region		
Start position	6171835	108147489
Contig	chr1	chr3
Gene		
Gene symbol	CHD5	MYH15
Full name	Chromodomain helicase DNA binding protein 5	Myosin, heavy chain 15
Variation description		
Variation identifier		
Source name	dbSNP	dbSNP
Identification	rs139581412	rs779562147
Version	134/150	144/150
URL	https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=139581412	https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=779562147
Alternate		
Variant type	Substitution	Deletion
[SLOT]:Variant	g.6171835G>A	g.108147489delC
Allele depth	40	110
Quality	1316.9	9790.86
Filtering		
Filter		
ID	MQRankSum_snp	QD_indel
Description	vc.isSNP() && MQRankSum < -12.5	vc.isIndel() && QD < 2.0
Filter status	1	1
Total depth	80	214
Genotype characterization		
Genotype	0/1	0/1
Genotype quality	99	99
Genotype probability	774,0,687	4167,0,4060

Table 3: Sample usage of the Sequence Variation archetype

Attribute	Use case 1	Use case 2
Reference Sequence		
Source name	NCBI	NCBI
Accession number	NC_000001	NC_000003
Version number	NC_000001.10	NC_000003.11
URL	https://www.ncbi.nlm.nih.gov/nuccore/NC_000001.10	https://www.ncbi.nlm.nih.gov/nuccore/NC_000003.11

Table 4: Sample usage of the Reference Sequence archetype

however, can include additional extensions of the *Observation* resource at the same hierarchical level (it grows horizontally, while the openEHR model grows vertically). This has to be taken into account while comparing, together with the different meaning of the “observation” term.

Attribute	Use case 1	Attribute	Use case 2
Substitution Variant		Deletion Variant	
Position substituted	6171835	Start position	108147489
Reference nucleotide	G	End position	-
New nucleotide	A	Deleted nucleotide(s)	C

(a) Sample usage of the Substitution Variant archetype

(b) Sample usage of the Deletion Variant archetype

Table 5

The comparison was carried out considering three types of data: context, derived and objective.

4.2.1 Context data and interpretations

In the FHIR[®] model, information about the context of the genetic test performed, the devices used, the specimen, the patient and the performer is given both in the *Observation* resource and in the *Sequence* resource (as a reference to another external resource). Similarly, in the openEHR model the *Genetic Test Result* archetype contains slots to include cluster archetypes (e.g., *Specimen*, *Medical Device*) that provide context information. The difference is that while in FHIR[®] this information is repeated in multiple places, the recursively nested openEHR approach allows to refer to the same entity multiple times, avoiding redundancy.

Genetic data are typically complemented by subjective information such as diagnosis or generic comments. In the FHIR[®] model, these are mainly represented within the *Genetics* profile of the *Diagnostic Report* resource. In our model, this type of data could be included in the *Genetic Test Result* archetype.

4.2.2 Derived data

Derived data consist of annotations from the bioinformatic analysis: transcript annotations, impact prediction, sequence conservation, etc. In the openEHR model these items are represented within the *Genetic Findings* cluster archetype, and the range of representable annotations can be broadened via extension slots. At present, FHIR[®] does not include explicit references to this type of data.

4.2.3 Objective data

Objective data describe the observed sequence variations. In the FHIR[®] standard, these elements can be found both in the *Sequence* (e.g., reference sequence, variant, quality) and in the *Observation-Genetics* resource (e.g., DNA variant type and ID, gene, allelic state), while in our model they are all included in the *Sequence Variation* archetype, in order to isolate the interpretative aspects from the purely objective variant data.

Our approach differs from the FHIR[®] one in two main respects: reference sequence and variant description. In FHIR[®], the reference sequence can be represented by the same *Sequence* resource used to describe the sample sequence, while in our model it is made available via a link to an external entity (repository, accession and version). In FHIR[®], the observed variant is also represented within the *Sequence* resource through the range of positions affected by the change(s), the reference allele and the observed one and the CIGAR string¹⁵, while in our model we use a different archetype for each variant type in the HGVS specifications.

4.3 Modeling issues

The first challenge encountered during the modeling process was how to represent the results of genetic tests conducted on more than one sample. This happens, for instance, in rare disease studies where patient data is more useful if compared to data from family members, or in oncology when cancer cells are compared to non-cancer cells from the same patient. The archetypes presented here are meant to be used for a single sample, with the assumption that any relationships with other samples are handled at a higher level, i.e., at the composition level.

Another critical aspect concerns the representation of the different types of variant. A simple approach would be to store the reference nucleotide, start position and observed nucleotide(s). This method is very similar to the one adopted in VCF files and works well for single nucleotide substitutions, but can be confusing for more complex variant types. For instance, for simple deletions the VCF REF and ALT strings must include the base before the event, while this is not required for complex substitutions¹⁶. To avoid this kind of ambiguity, we used a specific archetype to describe each type of variant.

4.4 Related work

Integration of genomic data into EHRs is the subject of several ongoing activities.

The EHR Integration (EHRI) workgroup of the Electronic Medical Records and Genomics (eMERGE) network aims to develop standards and methods for incorporating genomic data into EHRs and optimizing their utilization^{24,25}.

The Data Working Group of the Global Alliance for Genomics and Health (GA4GH) concentrates on the representation, storage and analysis of genomic data, with a focus on interoperability²⁶. The group developed a web API to allow the exchange of genomic information through a freely available open standard that models entities such as data requests, error messages and actual genomic data fragments²⁷.

The Harvard Medical Center for Biomedical Informatics developed the SMART Genomics API^{28,29}, an extension of the SMART (Substitutable Medical Applications, Reusable Technologies) platform that uses FHIR[®] as its base framework to store both Clinical and Genomics data. Following the FHIR[®] specifications, the team developed new resources and extensions, providing significant input to the HL7[®] Clinical Genomics Workgroup³⁰.

Finally, a first draft of archetypes for genomic data has recently been published in the Norwegian instance of the CKM by the Nasjonal IKT³¹. It consists of five archetypes that describe the patient's genome, the output of a genetic assessment, the protocol of a genetic laboratory analysis, the description of a variation and of the two alleles. Even though the model is well designed and accurate, it does have a few shortcomings. The *Genetic Lab Analysis* archetype, which describes the protocol used to perform a genetic test, does not support contextual information such as the patient's clinical conditions. In contrast, we represented genetic test results with a specialization of the existing *Laboratory Test Result* archetype, which contains an accurate description of both context data and the adopted protocol. Moreover, this is in line with openEHR best practice on resources reuse through specialisation³². The *Genetic Variant* archetype, together with its *Allele Details* extension, represents information about variations via plain text strings: a characterization (normal or pathogenic), a generic description, one or more reference sequences, etc. In our model, instead, we employ versionable entities (reference sequence, variant ID, etc.) that link to external databases, and we represent each variant type in structured form via a separate cluster archetype. This improves machine readability and makes the archetype more flexible and

easily adaptable to the rapid changes in reference sequences and bioinformatic tools. Finally, the IKT model lacks annotations and tools to enable variant filtering and parameter calculation, which we include in the cluster archetype that represents test findings.

4.5 Conclusions and future work

We have presented a model for representing genomic content (sequence variation analysis) in a structured form through openEHR archetypes, with the main goals of being machine readable, reusable and shareable. Moreover, each versionable resource or tool involved in the data production process is linked as an external object, allowing to keep track of the particular revision of each instance. We have assessed the feasibility of our approach by applying it to the rare diseases use case. Finally, we have discussed its interoperability with HL7[®] FHIR[®].

The archetypes described here are available at <https://github.com/crs4/openehr-genomics>. In the future, we plan to integrate their use in our production NGS analysis pipelines to formalize the results made available to clinical researchers.

References

1. E. D. Green, M. S. Guyer, and National Human Genome Research Institute, “Charting a course for genomic medicine from base pairs to bedside.,” *Nature*, vol. 470, pp. 204–13, feb 2011.
2. S. H. Beachy, S. Olson, A. C. Berger, and H. S. Policy, *Genomics-Enabled Learning Health Care Systems : Gathering and Using Genomic Information to Improve Patient Care and Research : Workshop Summary*. 2015.
3. A. G. Ury, “Storing and interpreting genomic information in widely deployed electronic health record systems,” *Genetics in Medicine*, vol. 15, pp. 779–785, oct 2013.
4. J. L. Warner, S. K. Jain, and M. A. Levy, “Integrating cancer genomic data into electronic health records.,” *Genome medicine*, vol. 8, p. 113, oct 2016.
5. “Welcome to openEHR.” <http://www.openehr.org/>. (Accessed on 07/20/2016).
6. “Clinical Knowledge Manager.” <http://www.openehr.org/ckm/>. (Accessed on 07/21/2016).
7. “openEHR Architecture Overview.” http://www.openehr.org/releases/BASE/latest/docs/architecture_overview/architecture_overview.html#_two_level_modelling_and_archetypes. (Accessed on 05/23/2017).
8. N. Aziz, Q. Zhao, L. Bry, D. K. Driscoll, B. Funke, J. S. Gibson, W. W. Grody, M. R. Hegde, G. A. Hoeltge, D. G. B. Leonard, J. D. Merker, R. Nagarajan, L. A. Palicki, R. S. Robertye, I. Schrijver, K. E. Weck, and K. V. Voelkerding, “College of American Pathologists’ laboratory standards for next-generation sequencing clinical tests.,” *Archives of pathology & laboratory medicine*, vol. 139, no. 4, pp. 481–93, 2015.
9. S. Pabinger, A. Dander, M. Fischer, R. Snajder, M. Sperk, M. Efremova, B. Krabichler, M. R. Speicher, J. Zschocke, and Z. Trajanoski, “A survey of tools for variant analysis of next-generation genome sequencing data,” *Briefings in Bioinformatics*, vol. 15, pp. 256–278, mar 2014.
10. L. G. Biesecker and R. C. Green, “Diagnostic Clinical Genome and Exome Sequencing,” *New England Journal of Medicine*, vol. 370, pp. 2418–2425, jun 2014.

11. R. C. Green, H. L. Rehm, and I. S. Kohane, “Clinical Genome Sequencing,” in *Genomic and Personalized Medicine*, pp. 102–122, Elsevier, 2013.
12. Y. Yang, D. M. Muzny, J. G. Reid, M. N. Bainbridge, A. Willis, P. A. Ward, A. Braxton, J. Beuten, F. Xia, Z. Niu, M. Hardison, R. Person, M. R. Bekheirnia, M. S. Leduc, A. Kirby, P. Pham, J. Scull, M. Wang, Y. Ding, S. E. Plon, J. R. Lupski, A. L. Beaudet, R. A. Gibbs, and C. M. Eng, “Clinical whole-exome sequencing for the diagnosis of mendelian disorders,” *The New England journal of medicine*, vol. 369, pp. 1502–11, oct 2013.
13. “dbSNP Home Page.” <http://www.ncbi.nlm.nih.gov/SNP/>. (Accessed on 07/22/2016).
14. G. A. Van der Auwera, M. O. Carneiro, C. Hartl, R. Poplin, G. del Angel, A. Levy-Moonshine, T. Jordan, K. Shakir, D. Roazen, J. Thibault, E. Banks, K. V. Garimella, D. Altshuler, S. Gabriel, and M. A. DePristo, “From FastQ Data to High-Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline,” in *Current Protocols in Bioinformatics* (A. Bateman, W. R. Pearson, L. D. Stein, G. D. Stormo, and J. R. Yates, eds.), vol. 11, pp. 11.10.1–11.10.33, Hoboken, NJ, USA: John Wiley & Sons, Inc., oct 2013.
15. H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis, R. Durbin, and . G. P. D. P. Subgroup, “The sequence alignment/map format and SAM-tools,” *Bioinformatics*, vol. 25, pp. 2078–2079, Aug 2009. btp352[PII].
16. “The Variant Call Format (VCF) Version 4 . 2 Specification.” <https://samtools.github.io/hts-specs/VCFv4.2.pdf>, 2015. (Accessed on 09/26/2017).
17. “Linkehr.” <http://www.linkehr.com/>. (Accessed on 02/28/2017).
18. “Observation laboratory test result at master openehr/ckm-mirror.” https://github.com/openEHR/CKM-mirror/blob/master/local/archetypes/entry/observation/openEHR-EHR-OBSERVATION.laboratory_test_result.v0.adl. (Accessed on 09/28/2017).
19. C. S. Richards, S. Bale, D. B. Bellissimo, S. Das, W. W. Grody, M. R. Hegde, E. Lyon, and B. E. Ward, “ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007,” *Genetics in Medicine*, vol. 10, pp. 294–300, apr 2008.
20. H. L. Rehm, S. J. Bale, P. Bayrak-Toydemir, J. S. Berg, K. K. Brown, J. L. Deignan, M. J. Friez, B. H. Funke, M. R. Hegde, and E. Lyon, “ACMG clinical laboratory standards for

- next-generation sequencing.,” *Genetics in medicine : official journal of the American College of Medical Genetics*, vol. 15, pp. 733–47, sep 2013.
21. J. T. den Dunnen, R. Dalgleish, D. R. Maglott, R. K. Hart, M. S. Greenblatt, J. McGowan-Jordan, A. F. Roux, T. Smith, S. E. Antonarakis, and P. E. M. Taschner, “HGVS Recommendations for the Description of Sequence Variants: 2016 Update,” *Human Mutation*, vol. 37, pp. 564–569, jun 2016.
 22. “Genomics - FHIR v3.0.1.” <http://hl7.org/fhir/genomics.html>. (Accessed on 04/26/2017).
 23. “Index - FHIR v1.0.2.” <https://www.hl7.org/fhir/>. (Accessed on 07/20/2016).
 24. “Welcome to eMerge > Collaborate.” <https://emerge.mc.vanderbilt.edu/>. (Accessed on 07/21/2016).
 25. “Electronic Medical Records and Genomics (eMERGE) Network.” <https://www.genome.gov/27540473/electronic-medical-records-and-genomics-emerge-network/>. (Accessed on 07/21/2016).
 26. “Home | Global Alliance for Genomics and Health.” <http://genomicsandhealth.org/>. (Accessed on 07/21/2016).
 27. “Schemas — GA4GH Schemas 0.0.1 documentation.” <https://ga4gh-schemas.readthedocs.io/en/latest/schemas/index.html#schemas>. (Accessed on 07/21/2016).
 28. R. Swaminathan, Y. Huang, S. Moosavinasab, R. Buckley, C. W. Bartlett, and S. M. Lin, “A Review on Genomics APIs,” 2015.
 29. J. L. Warner, M. J. Rioth, K. D. Mandl, J. C. Mandel, D. A. Kreda, I. S. Kohane, D. Carbone, R. Oreto, L. Wang, S. Zhu, H. Yao, and G. Alterovitz, “SMART precision cancer medicine: a FHIR-based app to provide genomic information at the point of care,” *Journal of the American Medical Informatics Association*, vol. 1, no. 615, p. ocw015, 2016.
 30. G. Alterovitz, J. Warner, P. Zhang, Y. Chen, M. Ullman-Cullere, D. Kreda, and I. S. Kohane, “SMART on FHIR Genomics: facilitating standardized clinico-genomic apps,” *Journal of the American Medical Informatics Association : JAMIA*, vol. 22, no. 6, pp. 1173–8, 2015.
 31. “Norwegian Nasjonal IKT Clinical Knowledge Manager – Clinical Genetics Incuba-

tor.” http://arketyper.no/ckm/OKM_nb.html#showProject_1078.43.53. (Accessed on 09/05/2016).

32. “Archetype Technology Overview.” http://www.openehr.org/releases/AM/latest/docs/Overview/Overview.html#_archetype_specialisation. (Accessed on 09/26/2017).